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Factors Altering Thyroid Hormone
Metabolism
by Jacob Robbins*
Thyroxine, the major secretory product ofthe thyroid gland, is metabolized in the peripheral
tissuesbyphenolicconjugation, deamination, decarboxylation, andacascadeofmonodeiodinations.
This brief review focuses on the deiodination reactions, which currently are under intensive
investigation. One product, 3,5,3'-triiodothyronine (T3), is the major active form ofthe thyroid
hormone, and about 80% of the T3 produced in the body is derived extrathyroidally.
Furthermore, agreaterfraction oftheT3found on nuclearreceptors in pituitary and brain cells
is derived intracellularly, as compared to liver and kidney cells. The latter tissues, on the other
hand, appear to be the source ofmost ofthe circulating T3. Another deiodinase, acting on the
nonphenolic ring ofT4, gives rise tothe hormonally inactive 3,3', 5'-triiodothyronine ("reverse"
T3 or rT3). A number of physiological and pathological events perturb the deiodination
pathway, leading to a decrease in T3 neogenesis and reciprocal changes in the circulating level
of T3 (which decreases) and rT3 (which increases). This so-called "low T3 syndrome" is also
produced by a number of pharmacological agents. The biological effects resulting from these
changes are incompletely understood, but they are potentially important in the body's
adjustment to stress and as a site of action of toxic agents. In addition, they are of obvious
importance clinically because of their influence on serum T3 and TSH levels, which are
commonly used tests of thyroid function.
The thyroid hormone after secretion from the
thyroid gland undergoes a number of metabolic
transfornations (1). Althoughthese werediscovered
and intensively investigated more than 25 years
ago, there was relatively little interest in the
subject until quite recently. Figure 1 shows the
diphenyl ether structure of the major secretory
product, thyroxine(T4). Triiodothyronine (T3), lacking
the 5'-iodine, is secreted in much smaller quantity.
One type ofmetabolic transformation takes place at
the phenolic hydroxyl group of the so-called beta
ring of T4 or T3. This consists of esterification by
glucuronic acid or sulfate and occurs primarily in
the liver and also in the kidney. The result is
inactivation and excretion ofthe hormone. Pharma-
cological agents such as phenobarbital (2) and
polychlorinated biphenyls (3), and environmental
influences such as cold exposure (4), can affect
these conjugation reactions and thus perturb hor-
mone disposal and, secondarily, hormone secretion.
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However, I will not discuss these reactions further
in this presentation. Another group of reactions
occurs atthe alanine side chain ofthe inneror alpha
ring. This involves deamination and decarboxylation
leading to the so-called acetic acid analogs which
are metabolically active. At the present time, little
is known about the quantities produced or about
their contribution to hormone action.
The third metabolic route involvesremoval ofthe
iodine atoms from the benzene rings. Formerly,
this was thought to be a concerted deiodination
leading only to iodide and the inactive thyronine
molecule. It is now recognized, however, that
stepwise deiodination isthemajorroute ofhormone
metabolism. This process also leads to both active
and inactive metabolites and is now the subject of
intensive investigation. It has also become clear
thatthese monodiodination reactions are influenced
by a number of physiological and pathological
events. In this account, I will discuss the deiodination
reactions and in particular will review some of the
information which has come to light about pharma-
cological effects on these reactions.
Removal of one of the outer ring iodines of
65/NH
COOH
Deamination and Decarboxylation
gives "Tetrac" and "Triac"
FIGURE 1. Structureofthyroxine (3,5,3', 5'-tetraiodo-L-thyro-
nine) and metabolic reactions at the phenolic hydroxyl and
the alanine side chain.
thyroxine leads to the formation of 3,5,3'-triiodo-
thyronine, a compound which is biologically more
active than thyroxine itself. On the other hand,
removal of one of the inner ring iodines gives the
so-called reverse triiodothyronine (3,3',5'-T3 or
rT3) which is not only devoid of hormone activity
but may actually have antihormone properties (5).
Essentially none of the reverse triiodothyronine is
derived from secretion per se by the thyroid gland.
Table 1 gives some quantitative data on the
production and secretion rates ofthyroxine and T3
which have been derived from a recent investiga-
tion. It should beunderstood thatthese are approx-
imate values, not only because of variations from
one laboratory to another, but also because they
are derived from kinetic studies which depend on
complete hormone exchange between plasma and
all tissues. It is now evident that T3 equilibration
does not occur in certain tissues, such as the
pituitary and the brain (7-9). Nevertheless, it is
clear that the major secretory product by far is
thyroxine. On the other hand, the production rate
ofT3 inthe body is almost 1/2 that ofthyroxine on a
weight basis. From data such as these, it can be
concluded that about 80% ofthe T3 appearingin the
bodyistheresultofextrathyroidal monodeiodination
of thyroxine and that almost half of the thyroxine
secreted by the gland is utilized for T3 formation.
Table 1. Production and secretion
hormones.a
rates of the thyroid
Production Secretion
rate, rate,
p.g/day % of total PR
T4 87 100
T3 34 24
rT3 36 2
aData from Chopra (6).
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FIGURE 2. Monodeiodination cascade of the iodothyronines.
The values in parentheses are the production rates of T4 in
intact man (6) or for T4 derivatives in three athyreotic
subjects receiving full T4 replacement (10). Other data give a
somewhat higher value for T3 generated from T4 (see Table
1).
Since T3 is hormonally more active than '1'4 anci may
in fact account for most of thyroxine's biological
activity, we can conceive of thyroxine as a
prohormone.
Figure 2 shows the cascade ofmonodeiodinations
which are now known to occur after thyroxine is
secreted fromthe gland. The arrows pointingto the
right indicate removal of iodines from the outer
ring while those pointing to the left indicate re-
moval ofinnerringiodines. It now appears that two
deiodinases carry out all these reactions; i.e., 3' or
5'-deiodinase and 3 or 5-deiodinase. As can be seen
from the production rates in terms of nanomoles
per day, similar amounts of T3 and reverse T3 are
formed and both are channeled through further
deiodination to form 3,3'-diiodothyronine, an inac-
tive metabolite. It is of interest that, whereas the
molar ratio of T4 to T3 production is about 4, the
molarratio ofT4toT3concentration intheplasmais
approximately 60. This is the result of the very
much more rapid disappearance rate ofT3 from the
circulation, which is at least in part due to its lower
affinity for the plasma transport proteins which
bind the thyroid hormones.
Table 2 shows that there is very much more
thyroxinethantriiodothyronineintheextrathyroidal
poolbut that its distribution volume is considerably
smaller than that of T3 (11, 12). Furthermore,
whereas thyroxine is almost equally distributed
between the plasma, where it is bound to the
transport proteins, the rapidlyturningoverhepatic
and renal pools, and the more slowly turning over
muscle, brain and other tissues, the bulk oftriiodo-
thyronine is found in the latter tissues. I should
state again, however, that these data are based on
the assumption that equilibrium exists. As already
indicated, this assumption is not strictly correct, at
least for T3.
Environmental Health PerspectivesTable2. Extrathyroidal distributionofthethyroidhormones.a
T4 T3
Distribution volume, liters 12 31
Extrathyroid pool, jig 930 40
Plasma, % 22 18
Liver, kidney, % 31 5
Muscle, brain, skin, % 44 75
aThe data are from primary sources discussed elsewhere (1).
A recent development of considerable interest is
illustrated by the work of Obregon et al. (8). They
administered simultaneously T4 and T3, labeled
with two different iodine isotopes, either by re-
peated injection or continuous infusion over a
period of five days. They then measured the T3 in
various tissues which was labeled by each of the
isotopes. If all ofthese tissues were in equilibrium
with the plasma, they would have found identical
isotope ratios. In fact, the ratios varied widely from
tissue to tissue. It is of interest that the brain had
the highest proportion of T3 derived from intracel-
lular T4 rather than from plasma T3. This indicates
clearly that the relative amounts of thyroxine and
its metabolites found in the plasma do not necessar-
ily reflect the proportions in a particular tissue
where the hormone is exertingits biological effects.
Related information was developed in Larsen's
laboratory (7, 9) in greater detail. Again using T4
and T3 labeled with different iodine isotopes, these
workers examined the T3 sequestered in the cell
nucleiwhere at least one ofthe hormone'sbiological
receptors is known to exist. The fraction ofnuclear
T3 which was derived locally within the tissue by
monodiodination of T4 was compared with that
reaching the tissue by diffusion from the plasma. In
the pituitary, half of the nuclear T3 was derived
locally, whereas in the liver this was only 1/4 and in
the kidney it was 1/7. In the cerebral cortex, 3/4 of
the nuclear T3 was derived locally from T4. T3 in
brain synaptosomes is also derived locally (13).
Some of the implications of these very important
experiments will be discussed later.
With this brief background on the deiodinative
metabolism of the iodothyronines, I now want to
describe some of the evidence which has come to
light concerning a number offactors which operate
to alter the amount ofhormone movingthrough the
various channels of metabolism. Table 3 lists sev-
eral which I have labeled "physiological" only to
differentiate them from the effects of various dis-
eases and pharmacological agents which I will
discuss later. One ofthe most striking variations is
that seen in the fetus where there is a very marked
reduction in the plasma level of T3 and in the
formation ofT3 from T4 (14, 15). At the same time,
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Table 3. "Physiological" factors affecting T4 deiodination.a
T3 rT3 TSH
Age
Fetus H, T l
Old age Ni
Fasting (carbohydrate) I t N
Cold exposure t
a The arrows indicate the direction of changes in plasma
levels, which can reflect changes in formation or degradation or
both. Alloftheseconditionsdecreaseperipheralconversion ofT4
to T3 except cold exposure.
there is a relative increase in the plasma level of
reverse T3. As will be seen, a general phenomenon
whichrunsthroughoutthese observations isthat T3
and reverse T3 are reciprocally related. Initially,
this was believed to be the result of opposite
changes in production of T3 and rT3 from their
common precursor, T4. It is now felt that it is more
likely the result of a modification only in the
5'-deiodination pathway, which simultaneously de-
creases the production of T3 and decreases the
degradation of rT3. However, alterations in rT3
production also may occur under come circum-
stances. Inthefetus, there is verylittle secretion of
TSH until after birth, perhaps related to variations
in T3 production within the thyrotrophic cells (16).
A second phenomenon listed on this figure is seen
in adults who are subjected to food deprivation,
particularly carbohydrate (1, 17). This also is
associated with a decrease in 5'-deiodination of
thyroxine and an increase inplasmarT3 (18). Itis of
interest here that TSH secretion and its circulating
levels are generally normal. This is quite unlike the
finding when circulating T3 is lowered as a result of
hypothroidism. In that case, there is a compensa-
tory increase in the production of TSH from the
pituitary. Since the serum thyroxine level is rela-
tively normal in fasting but not in hypothroidism,
this leads to the question as to whether the
pituitary can respond to thyroxine as well as to T3.
I will have more to say about this later.
Table 4 lists several diseases which are also
known to result in alterations in thyroxine
deiodination (1, 19, 20); they include liver disease,
kidney disease and a variety ofsystemic illnesses of
at least moderate severity. Surgical or other types
of severe stress can also be included here. All of
these are associated with diminished conversion of
thyroxine to T3 and decreased circulating levels of
T3. Reverse T3levels aregenerally eithernormal or
increased and TSH production is usually normal.
Furthermore, the patients are clinically euthyroid
despite serum T3 levels which are frequently in the
hypothyroid range. Collectively, these conditions
67have been called the "low T3 syndrome." From the
standpoint of clinical medicine, they are perhaps
more important for their perturbation of the tests
ofthyroid function than as an indicator ofabnormal
thyroid function requiring therapy. However, we
stillhave muchto learn about the clinical significance
of these alterations in T3 production.
The last two items in Table 4 concern hypothy-
roidism and hyperthyroidism. Very recent work
has shown that the deiodination ofthyroxine in the
liver and in the pituitary and brain in these
disorders is quite different (16, 21, 22). In hypothy-
roidism, there is a decreased formation ofT3 in the
liver, but an increased formation in the pituitary
and brain. In hyperthyroidism, the findings are the
opposite. In fasting, onthe otherhand, it was found
that hepatic formation of T3 from T4 is reduced
while it is normal or only slightly decreased in the
pituitary (21). These findings bear on the question
of how the rate of pituitary TSH secretion relates
to a particular circulating level of T3 (16), since it
appears to respond to the sum ofintracellularly and
extracellularly derived T3.
I now want to move on to the subject which is
central to the purpose of this symposium, and to
discuss the effects that pharmacological agents can
have on thyroid hormone deiodination. Table 5
summarizes results obtained with four drugs that
have been studied extensively in man as well as
experimental animals. In many of these experi-
ments, the use ofhypothyroid subjects on therapy,
or euthyroid subjects in whom thyroid gland func-
tion is replaced by T4 administration, has demon-
strated that the findings I will discuss are largely, if
not entirely, the result of alterations in peripheral
T4 metabolism.
Corticosteroid administration (e.g., 8 mg of dex-
amethasone perday) (23, 24) results in a prompt fall
in circulating T3, occurring within hours. This is
due to an inhibition ofits formation from thyroxine.
At the same time, there is an increase in plasma
reverse T3. It is quite possible that some of the
alterations observed in acute illness or stress,
discussed above, may result from an increase in
corticosteroid secretion.
Table 4. Diseases affecting T4 deiodination.a
T3 rT3 TSH
Liver disease I iTb TNb
Nephrosis l N N
Systemic illness T TNb
Hypothyroid l I T
Hyperthyroid T
a See footnote to Table 3.
b The more common findings when more than one is indicated.
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Table 5. Drugs affecting T4 deiodination.a
Drug class Example T3 rT3 TSH
Corticosteroid Dexamethasone I 1 I
Thiourylene Propylthiouracil I t I
Cholecystographic Iopanic acid T T
agent Ipodate
Other Amiodarone T T
a See footnote to Table 3.
The second agent listed is the thiourylene drug,
propylthiouracil (PTU). It was shown some years
ago that certain antithyroid drugs, PTU being one,
resulted in a slowing of thyroxine metabolism as
well as a decrease in its hormonal effect (4). The
other commonly used antithyroid drug, methimazol,
does not have this effect. More recent experiments
from a number of laboratories have clearly shown
that PTU and its congeners interfere with the
formation ofT3 in the peripheral tissues (1, 16, 25,
26). Again, reverse T3 in plasma is increased.
However, whereas5'-deiodination ofT4isdecreased
by propylthiouracil in liver, in the pituitary gland
T3 formation from T4 is unaffected (7, 16). This may
be due to a failure of propylthiouracil to enter the
pituitary cells (27). In studies with tissue homoge-
nates, it has been shown that PTU is a non-
competitive inhibitor of 5'-deiodinase (28, 29).
Interestingly, it is much less effective in inhibiting
5-deiodinase (30, 31).
A third type of compound which has recently
been shown to have a profound effect on thyroxine
deiodination includes the radiographic contrast
media, sodium ipodate (Oragrafin) and iopanic acid
(Telepaque) (Fig. 3) which are commonly employed
in cholecystography (16). These compounds mark-
edlyinhibitthe conversion ofT4toT3notonlyinthe
liverbut also in the pituitary gland (32-34) and they
are competitive inhibitors of 5'-deiodinase. It is of
interest that other rather similar compounds may
not have this effect on thyroxine metabolism. Since
they result in an increase in serium reverse T3, it is
apparent that the 5-deiodinase is not severely
impaired. An increase in TSH production occurs
despite the fact that the drugs may result in a
significant increase in the circulating thyroxine
level. Furthermore, these changes in serum hor-
mone levels are produced by a single oral dose of
the radiographic contrast agent in routine cholecys-
tography.
Afourthdrugwhichaffectsthyroxinedeiodination
is amiodarone, a compound widely used in Europe
as an antiarrhythmic and antianginal drug.
Amiodarone causes a prompt fall in the circulating
T3 level and an even greater increase in circulating
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FIGURE 3
reverse T3 (35). Thyroxine, on the other hand,
remains constant and the changes in circulating T3
are accompanied by an increase in TSH secretion.
The mechanism of action of amiodarone has not
been elucidated.
A fifth drug having similar, but less dramatic,
effects is propranolol, a 3-adrenergic blocking agent
often used to treat hyperthyroidism (1, 16, 36). It
appears that this action is unrelated to its anti-
adrenergic effect.
To summarize the results on the drugs I have
discussed, all of them cause a decrease in T3
production from T4 and a reciprocal increase in
plasma reverse T3 level. The effects on TSH
production, on the other hand, are not the same for
each agent. Amiodarone and especially iopanoic
acid result in an elevation ofTSH which, at least in
the case of iopanoic acid, appears to result from a
decrease of T3 production from T4 within the
pituitary thyrotroph cells. In the case ofcorticoste-
roid administration, there is a decrease in TSH
which probably results from an inhibitory effect of
corticosteroid itself on the thyrotroph. In the case
ofpropylthiouracil, TSH isincreased eventhough it
has been shown that this drug does not inhibit the
formation of T3 from T4 within the pituitary cell.
This indicates, as one might expect from the fact
that half of the nuclear T3 in the pituitary is
derived from the plasma, that not all of the feed-
back inhibition of TSH secretion is by way of
intracellular thyroxine metabolism.
In this discussion, I have attempted to review
some ofthe recent developments in our knowledge
of thyroxine deiodination. In particular, I have
shown that this metabolism is affected by a number
ofrather different chemical agents, and we arejust
beginning to develop an understanding of the
complexity of these metabolic events. It is clear
that the extrathyroidal formation ofT3 from the T4
which is secreted by the thyroid gland is the major
pathway through which thyroid hormone exerts its
effects. We now knowthat the kinetics offormation
of T3 is quite different in different tissues. Most
studied have been the rapidly metabolizing tissues
such as the liver and the kidney, which appearto be
the major source of the circulating T3, and the
pituitary gland, which isthe site offeedbackcontrol
of thyroid secretion. Recent data indicate that the
events in brain cells resemble more those in pitu-
itary than in liver. We have also seen that different
chemical agents can have different effects in the
pituitary compared tothe liver, and this is reflected
in differences in TSH secretion, on one hand, and
on T3 circulating levels on the other. Still to be
developed by further experimentation is an under-
standing of how the conversion of T4 to T3 is
involved in hormone action in each ofthe tissues on
which thyroid hormone exerts its effects. At this
time, it seems likely that circulating T3, originating
in liver and kidney, may be the major source of
active hormone for tissues such as muscle, whereas
the circulating T4 may be a more important source
for pituitary and brain cells.
With respect to the subject ofthis conference, it
is clear that these metabolic events affecting the
thyroid hormone are potential sites of action of a
variety of toxic agents. It is almost certain that in
the near future many additional chemicals acting on
these processes will be discovered.
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